Dr Julie Guillermet-Guibert is the leader of « SigDYN-Integrated cell signalling » research team, labelled by French Academic Research Institutions Inserm/CNRS/Université Paul Sabatier. Her laboratory is located in Centre de Recherches en Cancérologie de Toulouse, France. The questions underlying the following matters, “Which are the distinctive features of normal, cancer initiating and cancer cell signalling in physiopathological conditions? How can we use this knowledge for better diagnosis and therapy?”, has been the driving force in her career. She joined Inserm in 2010 as a permanent Researcher with the main objective of studying the unique biological features of oncogenic PI3K-driven signalling in pancreatic and ovarian biology. Cancer is one type of signalling disease where mutations, epigenetic events or organ context skew normal cell signalling. In this sense, the innovative genetically engineered mouse models developed in Guillermet-Guibert’s lab allows to decipher the biological mechanisms by which oncogenic pathways perturb normal tissue homeostasis. It helps to understand the multi-step process of the disease from the initiation to metastatic stages, as well as signalling adaptation to cancer treatments.